China: How To Construe A Close-Ended Claim Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd. Et.Al. v. HU Xiaoquan (Article No. 22 From "China Patent Case Review 2015" By Beijing East IP Ltd.)

Injection Consisting of Adenosine Disodium Triphosphate and Magnesium Chloride

Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd. et.al. v. Hu Xiaoquan - How to Construe a Close-ended Claim (Civil Judgment (2012) Min Ti Zi No. 10 by the Supreme People's Court on December 20, 2012)

When patent claims are granted a patent right, the public will determine the extent of patent protection in accordance with the relevant regulations and the terms of patent claims, and then decide what business strategy to apply. If a patentee fails to come up with a proper manner of drafting the claims during the patent prosecution for various reasons, and chooses close-ended claim which has a relatively narrow extent of protection, then the granted patent claims, when enforced, cannot cover the desired extent of protection. The highlight of this case is the confirmation that generally a close-ended claim of a chemical composition shall be construed as the composition merely consisting of the indicated components, and including no other components but impurities in a normal amount, while adjuvants do not belong to the impurities.

The patentee, HU Xiaoquan, owns a patent for invention No. ZL 200410024515.1, titled "Process for the Preparation of an Injection of Adenosine Disodium Triphosphate and Magnesium Chloride," wherein claim 2 recites the additional technical features, "a freeze-dried powder injection of adenosine disodium triphosphate and magnesium chloride for injection, consisting of adenosine disodium triphosphate and magnesium chloride at the ratio by weight of 100 mg to 32 mg."

The alleged product, adenosine disodium triphosphate and magnesium chloride for injection, is also an injection in the form of white or off-white freeze-dry lumps or powders. The main components of the freeze-dry powder are adenosine triphosphate disodium salt at a dosage of 100 mg and magnesium chloride at a dosage of 32 mg. However, in the process of the preparation of the alleged product, arginine and sodium bicarbonate, are added.

Both the Jinan Intermediate People's Court for the first instance and the Shandong High People's Court for the retrial held that the adjuvants in the alleged product are not the main components, and do not affect the composition, the weight ratio of "adenosine triphosphate disodium and magnesium chloride" in the injection. The alleged product has the same features as the patented product, which fell into the scope of protection of the patent at issue, and constitutes infringement.1

The alleged infringers, Shanxi Zhendong Taisheng Pharmaceutical Co., Ltd. et.al., filed a request for retrial with the Supreme People's Court, arguing that claim 2 of the patent is a close-ended claim, so the infringement cannot be established as long as the alleged product comprises any other component which is not recited in the claim, regardless of whether other component is an active ingredient.

After hearing the Supreme People's Court considered that the controversial focus of this case is on the extent of protection of a close-ended claim, i.e. claim 2.

The Supreme People's Court held that in order to safeguard the reliance interest of the public in the claim scope of granted patent right, when a patent infringement proceeding involves the extent of protection of a patent, a close-ended claim shall generally be interpreted as not including any component or process step other than those recited in the claim. When drafting the claims, the patentee can choose, according to the specific situations, an appropriate drafting manner among an open-ended mode, a close-ended mode, a close-ended mode for active components, and a partially close-ended mode, to obtain a proper extent of patent protection. The claim of the patent concerned (i.e. claim 2) explicitly employs the transition phrase "consisting of" for a closed-ended mode as specified in the Guidelines for Patent Examination, therefore, it is a close-ended claim and its claim scope should be determined according to the normal interpretation of a close-ended claim. That is, the freeze-dry powder injection of adenosine disodium triphosphate and magnesium chloride for injection claimed by claim 2 of the patent concerned contains only adenosine disodium triphosphate and magnesium chloride, but no other component, except for impurities in a normal amount. However, adjuvants do not belong to impurities, and an injection containing adjuvants is thus excluded from the scope of claim 2 of the patent concerned.

Based on the above interpretation, the exclusion of the other components is also an inherent feature of a close-ended claim. Compared with claim 2 of the patent concerned, the alleged product further comprises arginine and sodium bicarbonate, and therefore it does not constitute infringement. The Supreme People's Court ultimately reversed the judgments of the first instance and retrial.

Remarks

First, Rule 6 of Interpretations of the Supreme People's Court on Certain Issues Concerning the Application of Law in the Trial of Patent (hereinafter, referred to as "the Interpretation (2009)") interprets the application of the doctrine of prosecution history estoppel in patent infringement dispute cases. To enhance operability, this Interpretations emphasizes on the restrictive amendments or observations actually made by a patent applicant or patentee. The doctrine of prosecution history estoppel applies regardless of 1) whether such amendments or observations are made on the patent applicant or patentee's own initiative or in answer to the examiner's invitation, 2) whether there is any causal legal relationship between such amendments or observations and approval of patent right, or 3) whether such amendments or observations are ultimately accepted by the examiner.2

In this case, the applicant of the patent concerned had tried to amend the description and claims to read "the main components consist of adenosine triphosphate disodium and magnesium chloride" in response to the second office action issued by the State Intellectual Property Office during the substantive examination of the patent application. However, the examiner rejected the amendments for "going beyond the scope of disclosure contained in the initial description and claims" and hence violated the provisions under Article 33 of the Chinese Patent Law. In the end, the applicant amended the product claims as the approved.

Second, Rule 7 of the Interpretation (2009) stipulates that the all-limitations rule applies to a determination of patent infringement. An accused technical solution will be determined to fall into the scope of protection of a patent claim as long as the accused technical solution contains all the limitations of the claim. It does not matter whether the accused technical solution contains any additional limitation. However, for a closed-ended claim to a composition of matters, if an accused technical solution contains other components than those explicitly recited components of the claim, then the accused technical solution shall be found non-infringing instead of falling into the claim scope by construing the other components as "additional limitation," which does not relate to the finding of an infringement.3

In this regard, the Beijing High People's Court adds in Guidelines for Determining Patent Infringement issued in year 2013 that: a closed-ended claim to a composition of matters shall be interpreted as containing only the explicitly recited components, with the exception of any additional technical features in an accused technical solution that does not have any substantive influence on the properties, and technical effects of the composition, or as inevitable impurities in a normal amount. In practice, however, sometimes it is a tough problem to inquire whether an influence is a "substantial" influence. Moreover, chemistry is an experimental science, and the technical effects need to be verified by providing a large volume of experimental data. It is highly possible that both plaintiff and defendant will provide experimental data in favor of him or herself, which may further complicate the courts to verify the experimental data as evidence.

In this case, the courts of first instance and retrial both held that the adjuvants are not the main components, and the alleged product has all the technical features of the patented product. The courts of first instance and retrial are obviously wrong, as the alleged product having the additional components "arginine and sodium bicarbonate" does not infringe the asserted patent claim in a close-ended mode either literally or under the doctrine of equivalents. Meanwhile, the Supreme People's Court clarified the applicability of the doctrine of equivalents to patent infringement of a close-ended claim, where it indicate that once a patentee chooses a close-ended claim, it means that the patentee has explicitly excluded any component or process step other than those recited in the claim from the scope of patent protection, and it is not justifiable for the patentee to re-claim the surrendered subject matters through the doctrine of equivalents. The doctrine of equivalents shall be applied on a limitation-by-limitation basis rather to the "invention as a whole".

Last, as far as this case is concerned, the drafting of the patent application contains many flaws, and this is the main reason why the asserted patent claim cannot cover the alleged product. If the patentee had recognized the restriction on the extent of protection of a close-ended claim when drafting the patent application, he might avoid using a closed-ended mode, and choose an open-ended claim for a broader scope of protection. In prosecuting the patent application, the patentee had tried to amending the completely close-ended claim to the injection to a closed-ended mode of the main components of the injection. However the amendment was rejected for "going beyond the scope of disclosure contained in the initial description and claims". This defeated the patentee's attempt to expand the claim scope. From this we can learn that it would be better to make the disclosure of the description enough to leave room for later amendments to claims.

Injection Consisting of Adenosine Disodium Triphosphate and Magnesium Chloride Case - PowerPoint Presentation (Chinese Version)

Footnotes

1. The Supreme People's Court ordered the Higher People's Court of Shandong to retry the case due to the erroneous application of the law in second instance.

2. Kong Xiangjun, Wang Yongchang, Li Jian. Certain Issues on the Application of Interpretations of the Supreme People's Court on Certain Issues Concerning the Application of Law in the Trial of Patent [J]. Electronic Intellectual Property, 2012, (2): 80-84. .

3. KONG Xiangjun, WANG Yongchang, LI Jian. Certain Issues on the Application of Interpretations of the Supreme People's Court on Certain Issues Concerning the Application of Law in the Trial of Patent [J]. Electronic Intellectual Property, 2012, (2): 80-84.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions